The fact that these two enzymes are extensively studied in the context of oncogenesis, tumor survival and metastasis, and that ILK and TTK inhibitors are being developed for this purpose29–31, adds another dimension to our results that show that inhibition of these enzymes affects T-cell activation that may lead to their reduced anti-tumor activity. Here, ILK is linked to neoplasm.